 |
PERTH, Australia, March 17, 2026 /PRNewswire/ — BioCina Pty Ltd., a world end-to-end Contract Improvement and Manufacturing Organisation (CDMO) introduced it has initiated a complete CMC (Chemistry, Manufacturing, and Controls) program for the development of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute therapy of delirium in intensive care settings.
Sterile injectable manufacturing utilizing a closed isolator system, BioCina Perth
A reformulated RLS-2201 is being produced at BioCina’s sterile manufacturing facility in Perth, below circumstances designed to substantiate the reproducibility and robustness of the manufacturing course of. The reformulated RLS-2201 will assist ICH-aligned stability research required for regulatory submission and supply early provide for Patrys’ deliberate first-in-human scientific actions.
“We’re proud to be advancing RLS-2201 alongside a world-class CDMO associate whose deep manufacturing experience and technical capabilities are proving instrumental in de-risking this program. Their collaborative method to regulatory engagement offers us robust confidence as we transfer towards scientific trials. Collectively, we imagine RLS-2201 has the potential to handle a important unmet want within the therapy of delirium in acute hospital settings,” stated Dr. Samantha South, CEO, Patrys.
The initiation of CMC actions represents a major de-risking step for the RLS-2201 program. By validating the manufacturing course of for scientific readiness at this stage, Patrys and BioCina are establishing a technically sound and regulatorily defensible pathway towards scientific trial entry, focused for the second half of 2026. This engagement additional strengthens BioCina’s partnership with Patrys, reflecting BioCina’s dedication to supporting shoppers at each stage of their product growth journey.
“We’re thrilled to assist Patrys’ journey for RLS-2201. BioCina’s 50 years of expertise within the growth and manufacturing of sterile injectables is greater than only a functionality. We guarantee companions like Patrys can progress to clinic with confidence, and maintain the main target the place it belongs – bettering affected person outcomes,” stated Dr. Tommy Broudy, CEO, BioCina.
About BioCina
BioCina is a world end-to-end Contract Improvement and Manufacturing Organisation (CDMO) with over 50 years of sterile Drug Product manufacturing expertise, serving shoppers throughout the U.S., Europe, and Asia Pacific. With amenities recognised by the US FDA, EMA, TGA, and different key regulatory authorities, BioCina delivers Drug Substance and Drug Product options from early growth by to industrial scale.
BioCina’s capabilities span sterile injectable manufacturing of small and enormous molecule merchandise in a number of codecs, in addition to microbial biologics, pDNA, mRNA and LNP-based modalities. Partnering with BioCina in Australia offers shoppers with entry to one of many world’s most engaging R&D tax incentive packages, providing a significant value benefit all through growth and manufacture.
For extra data, go to www.biocina.com
About Patrys
Based mostly in Perth, Australia, Patrys, (ASX: PAB), is a clinical-stage biotechnology firm advancing a dual-platform technique combining progressive antibody therapeutics with a near-term CNS pharmaceutical program. Patrys’ deoxymab platform includes novel cell-penetrating antibodies focusing on intracellular illness mechanisms with a deal with immune-mediated inflammatory and different high-unmet-need indications.
Patrys’ CNS program, RLS-2201, is a proprietary injectable reformulation of quetiapine for the therapy of delirium in intensive, aged and palliative care setting, advancing through the FDA 505(b)(2) regulatory pathway. Collectively, these platforms place Patrys as a catalyst-rich, balanced growth firm, combining a de-risked reformulation asset with longer-term biologics innovation.
For extra data, go to www.patrys.com
Media Contact
media@biocina.com
Picture – https://laotiantimes.com/wp-content/uploads/2026/03/patrys_release_image_250225_8335.jpg
Emblem – https://laotiantimes.com/wp-content/uploads/2026/03/biocina_new_logo.jpg
